Pasithea Therapeutics获得ALS协会100万美元资金,研究Pas-004在治疗ALS中的疗效、安全性和耐受性

美股速递
Nov 25

Pasithea Therapeutics获得ALS协会100万美元资金,用于研究Pas-004在治疗肌萎缩侧索硬化症(ALS)中的疗效、安全性和耐受性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10